

**Abacavir**

## Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
 Oral > Solid: 300 mg tablet (as sulfate)

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Abacavir + lamivudine**

## Section

Fixed-dose combinations of antiretrovirals  
 Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Abacavir + lamivudine + lopinavir + ritonavir**

## Section

Fixed-dose combinations of antiretrovirals  
 Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral  
 granules

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Atazanavir**

## Section

Antiretrovirals > Protease inhibitors  
 Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Atazanavir + ritonavir**

## Section

Antiretrovirals > Protease inhibitors  
 Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

**Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate**

## Section

Fixed-dose combinations of antiretrovirals  
 Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil  
 fumarate equivalent to 245 mg tenofovir disoproxil)

## Indications

Human immunodeficiency virus disease  
 without mention of associated disease or  
 condition, clinical stage unspecified

## Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Darunavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Didanosine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution

Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dolutegravir

### Section

Antiretrovirals > Integrase inhibitors

Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Dolutegravir + lamivudine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz

### Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors  
Oral > Solid: 600 mg tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + emtricitabine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals  
Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + lamivudine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals  
Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Liquid: 10 mg per mL  
Oral > Solid: 200 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir alafenamide

### Section

Fixed-dose combinations of antiretrovirals  
Oral > Solid: 200 mg + 25 mg + 25 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

### Section

Fixed-dose combinations of antiretrovirals  
Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Emtricitabine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

## Emtricitabine + tenofovir alafenamide

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Indinavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 400 mg (as sulfate)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

### Section

Medicines for prevention of HIV-related opportunistic infections

Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

### Indications

Other specified prophylactic measures

## Lamivudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 150 mg tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lamivudine + nevirapine + zidovudine

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg

Tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lamivudine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals

### Indications

Therapeutic equivalent to emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to emtricitabine + tenofovir for

Contact with or exposure to human immunodeficiency virus

## Lamivudine + zidovudine

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Lopinavir + ritonavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)

Oral > Solid > dosage form: 40 mg + 10 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Nelfinavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 250 mg (as mesilate)

Oral > Other: 50 mg per g oral powder

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Nevirapine

### Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > dispersible tablet: 50 mg

Oral > Solid > tablet: 200 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Raltegravir

### Section

Antiretrovirals > Integrase inhibitors

Oral > Liquid: 100 mg granules for oral suspension

Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ritonavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Saquinavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 200 mg; 500 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Stavudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 5 mg per 5 mL powder for oral solution

Oral > Solid: 15 mg; 20 mg; 30 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Tenofovir disoproxil fumarate

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

## Zidovudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > tablet: 300 mg

Oral > Solid > capsule: 250 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

